This statement can also be applied to the selective CHK1/2 inhibitor prexasertib, which showed an increased sensitivity to platinum and olaparib in mouse tumor transplantation models and monotherapy efficacy in BRCA-wildtype platinum-resistant ovarian cancer (191, 192). This evidence concerns the gene CHEK1 and neoplasm.